Free Trial

Baillie Gifford & Co. Sells 382,652 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals logo with Medical background

Key Points

  • Baillie Gifford & Co. has reduced its stake in Alnylam Pharmaceuticals by 9.5%, selling 382,652 shares during the first quarter, while still maintaining ownership of 3,657,607 shares.
  • Analysts have varied price targets for ALNY, with Citigroup raising their target from $364 to $404, while Morgan Stanley decreased theirs from $284 to $268, indicating diverging sentiment among market experts.
  • CEO Yvonne Greenstreet sold 31,640 shares of Alnylam stock worth approximately $9.6 million, representing a 39.26% decrease in her ownership following the transaction.
  • Five stocks we like better than Alnylam Pharmaceuticals.

Baillie Gifford & Co. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,657,607 shares of the biopharmaceutical company's stock after selling 382,652 shares during the period. Alnylam Pharmaceuticals accounts for approximately 0.9% of Baillie Gifford & Co.'s investment portfolio, making the stock its 26th biggest position. Baillie Gifford & Co. owned approximately 2.81% of Alnylam Pharmaceuticals worth $987,627,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ALNY. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $28,000. Whipplewood Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Colonial Trust Co SC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. Finally, Washington Trust Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 53.5% in the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Jefferies Financial Group upped their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a research note on Wednesday, July 16th. Finally, Truist Financial assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $347.75.

Read Our Latest Stock Analysis on Alnylam Pharmaceuticals

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Up 0.7%

NASDAQ ALNY traded up $2.12 during mid-day trading on Tuesday, hitting $326.91. The company's stock had a trading volume of 319,787 shares, compared to its average volume of 891,778. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The company's 50 day simple moving average is $312.22 and its 200 day simple moving average is $275.76. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $333.70. The firm has a market capitalization of $42.63 billion, a price-to-earnings ratio of -156.41 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the business posted ($0.16) earnings per share. Alnylam Pharmaceuticals's revenue was up 20.2% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Recommended Stories

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?

Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines